Share
 
Title
Code
Session Type
Channel
Date Time
Chair:

OA06.01 Pharmacokinetics, safety, and vaginal bleeding associated with continuous versus cyclic 90-day use of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy
Sharon ACHILLES, University of Pittsburgh, United States
Abstract

OA06.02 Randomized, placebo-controlled trial of safety, pharmacokinetics, and pharmacodynamics of 90-day intravaginal rings (IVRs) releasing tenofovir (TFV) with and without levonorgestrel (LNG) among women in Western Kenya
Nelly MUGO, University of Washington, Kenya Medical Research Institute, Kenya
Abstract
OA06.03 Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of a multipurpose prevention vaginal ring containing tenofovir and levonorgestrel
Andrea THURMAN, CONRAD, United States
Abstract

OA06.04 Heterosexual couples' preferences for dual-purpose prevention products for HIV and pregnancy prevention: the CUPID Study (MTN-045) in Uganda and Zimbabwe
Alexandra MINNIS, RTI International, United States
Abstract

OA06.05 A phase I study to assess safety, pharmacokinetics and pharmacodynamics of a topical multipurpose prevention insert containing tenofovir alafenamide fumarate and elvitegravir dosed vaginally
Andrea THURMAN, CONRAD, United States
Abstract

OA06.06 Live Q&A